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Abstract 
Background: Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle 
cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no 
reported cases of hepatotoxicity secondary to zanubrutinib. We report the first case of severe liver injury due to 
zanubrutinib.
Case presentation: A 56-year-old Caucasian male with a history of relapsed lymphoplasmacytic lymphoma was 
admitted to the hospital with new-onset jaundice, choluria, and pruritus for 10 days. He had been on zanubrutinib 
as part of a clinical trial for 30 months. His blood profile showed a severe hepatocellular injury with jaundice (alanine 
transaminase 2474 IU/L and total bilirubin 141 umol/L with mild coagulopathy). He had an extensive work-up includ-
ing virology, autoimmune, and metabolic profiles in addition to abdominal ultrasound with no alternative explanation 
found for his liver injury. Zanubrutinib-induced liver injury was suspected, and causality assessment by the updated 
Roussel Uclaf Causality Assessment Method score showed a probable causal relationship with zanubrutinib. His liver 
histology was also consistent with drug-induced liver injury. His liver biochemistry improved following cessation of 
zanubrutinib and normalised after 8 weeks.
Conclusion: We report the first case of severe liver injury secondary to zanubrutinib after 30 months of treatment. 
This case raises clinical awareness regarding zanubrutinib-induced liver toxicity and the importance of drug with-
drawal in the event of liver injury.
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Background
Idiosyncratic drug-induced liver injury (DILI) is an 
important cause of acute liver failure in Europe and the 
United States (US) [1, 2] and is one of the most common 
reasons for drug withdrawal from the pharmaceutical 
market [3, 4]. These implications and its idiosyncratic 
nature pose a particular challenge both to clinicians 
and the pharmaceutical industry, who must be vigilant 
for liver-related adverse effects in new drugs. The type 
of liver injury is classified as hepatocellular, cholestatic, 
or mixed depending on the pattern of liver profile at the 
time of injury. Establishing a temporal relationship is 
crucial in making the diagnosis of DILI and, the updated 
Roussel Uclaf Causality Assessment Method (RUCAM) 
is the most common diagnostic tool used in clinical prac-
tice and trials for DILI definitions and inclusion [5, 6]. 
The mainstay of management of DILI is establishing the 
diagnosis and stopping the offending drug, which often 
results in the resolution of liver injury. However, in severe 
cases, DILI may progress to acute liver failure, requiring 
liver transplantation or leading to death [5].
Waldenström’s macroglobulinaemia (WM) is a 
chronic, indolent, B-cell lymphoproliferative disorder 
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characterised by bone marrow infiltration with lymphop-
lasmacytic cells that secrete monoclonal immunoglobu-
lin M (IgM) and activate the B-cell receptor signalling 
complex, of which Bruton tyrosine kinase (BTK) is a cru-
cial enzyme [7, 8]. BTK inhibitors have recently emerged 
as an effective treatment option for relapsed WM. Zanu-
brutinib is a novel potent BTK inhibitor that has shown 
a good safety profile in clinical studies [9]. We report 
the first case of severe liver injury following zanubruti-
nib therapy with a literature review of BTK inhibitors-
induced liver injury.
Case presentation
The case involved a 56-year-old Caucasian man who was 
diagnosed with Waldenström’s macroglobulinaemia at 
the age of 35 and previously treated with fludarabine and 
cyclophosphomide chemotherapy and plasma exchange. 
His past medical history also included mild psoriasis 
and being overweight (BMI 30). He did not have any 
regular medication. He provided a history of drinking 
300 g of alcohol a week and had been a lifelong smoker 
of 10 cigarettes per day. Following a 10-year monitoring 
period when he was asymptomatic, his paraprotein levels 
increased significantly, and he had widespread lymphad-
enopathy on cross-sectional imaging. His bone marrow 
biopsy showed 20–30 % infiltration with low-grade lym-
phoplasmacytic lymphoma and MYD88 disease with 
CXCR4 wild type.
He subsequently participated in phase 3 BeiGene ran-
domised clinical trial comparing zanubrutinib with ibru-
tinib for relapsing WM, and he was randomised to the 
zanubrutinib arm. He took zanubrutinib 160  mg twice 
daily continuously in addition to aciclovir and co-tri-
moxazole as prophylaxis for opportunistic infections. His 
blood profile was monitored every 4 weeks, as shown in 
Fig. 4. After 28 months of treatment, he had an asympto-
matic increase in transaminases and total bilirubin (TB), 
but he continued to take the drug. Following 8 weeks, 
he developed pale stools, dark urine, pruritis and jaun-
dice and was admitted to the emergency department. He 
had no clinical signs of liver failure on examination, and 
his admission blood profile showed markedly elevated 
transaminases: ALT 2474 (upper limit of normal (ULN): 
45 IU/L), AST 1257 (ULN: 35 IU/L), ALP 114 (ULN: 130 
IU/L), TB 141 (ULN: 21 umol/L), PT 14 (ULN: 12 s). He 
was not exposed to any new medication or herbal rem-
edies in the 6 months prior to the onset of his symptoms. 
Zanubrutinib was withheld as a suspected cause of liver 
injury, and a full liver screen was undertaken. His liver 
ultrasound showed a non-dilated biliary tree and a nor-
mal outline of the liver with echo-bright texture in keep-
ing with fatty changes. His serological liver screen was 
negative, excluding other possible causes of liver injury; 
results are summarised in Table 1.
The liver injury was hepatocellular with an R-value 
of 63.2, and the updated RUCAM causality assessment 
score for zanubrutinib was 7, indicating “probable drug-
induced liver injury” [6]. He undertook a liver biopsy, 
which showed patchy necrosis, cholestasis and moder-
ate to severe lobular and portal inflammation suggestive 
of a DILI without any evidence of alcohol-related liver 
disease, as shown in Figs. 1 and 2. Due to his underlying 
lymphoplasmacytic lymphoma, portal lymphoid infiltra-
tion was further characterised by immunohistochemis-
try, and the features were in line with a reactive lymphoid 
infiltrate, with no evidence of light chain restriction, as 
shown in Fig. 3.
Patient’s liver enzymes improved following drug ces-
sation, and he was discharged after a 9-day long admis-
sion. His liver profile normalised 28 days after discharge 
(Fig. 4), and his Zanubrutinib had been stopped perma-
nently. He was started on bendamustine and rituximab 
due to the rise in his paraprotein levels, and his liver 
enzymes remained within normal range.
Discussion and conclusion
Zanubrutinib is an orally available small-molecule inhibi-
tor of Bruton’s tyrosine kinase (BTK). It is the third drug 
in this class having received approval for treatment of 
refractory mantle cell lymphoma after ibrutinib and 
acalabrutinib. It has been approved in the USA since 
2019 and has been under evaluation for use in other B 
cell disorders. Safety data from pre-licensing clinical tri-
als showed that zanubrutinib is generally well tolerated, 
with frequent but mild side effects. Although mild eleva-
tions in liver enzymes were frequent, with less than 1 % of 
patients developed grade 3 or 4 ALT or bilirubin eleva-
tion, no severe hepatic impairment was reported [10, 11]. 
Combined data drawn from over 600 patients showed 
that LFT abnormalities were frequent but often mild. 
ALT elevations arose in 28 % and bilirubin levels in 24 % 
of subjects but were above five times the upper limit of 
normal (ULN) in less than 1 %. There were no reports of 
clinically apparent liver injury or early discontinuation 
because of liver injury or liver-related deaths [10]. More-
over, phase 1 clinical trials of Zanubrutinib in patients 
with B cell malignancies did not report hepatotoxicity or 
ALT elevation [12, 13].
To compare liver toxicity from zanubritinib with 
other BTK inhibitors, we reviewed the literature and 
summarised the available evidence from case reports of 
BTK-inhibitors-induced liver injury published to date 
in Table  2. Ibrutinib was the first BTK inhibitor to be 
approved by the FDA in 2015, with no hepatotoxicity 
reported before FDA approval. Since then, four case 
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reports have highlighted its potential risk of severe liver 
injury and acute liver failure [14–17]. Furthermore, out 
of 36,732 ibrutinib-related reports made to the WHO, 
509 were of hepatobiliary adverse reaction including 62 
described as hepatic failure [18]. Moreover, the results 
of the phase 3 clinical trial comparing ibrutinib with 
zanubrutinib in patients with WM have recently been 
published. Following a median treatment duration of 
Fig. 1 Histopathological changes of portal tracts in zanubritinib-induced liver injury. A Prominent portal and interface inflammation; B high-power 







Fig. 2 Histopathological changes of liver lobules in zanubritinib-induced liver injury: Lobular inflammation with spotty necrosis (D), ballooning (E) 
and cholestasis (F)
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over 18 months, ibrutinib had to be stopped in 2% of 
patients due to hepatitis and drug-induced liver injury, 
whereas there was no report of liver injury in the 
zanubritinib arm. Acalabrutinib was the second BTK 
inhibitor to be approved in 2017. To date, there are no 
case reports of acalabrutinib-induced liver injury. How-
ever, there are three reports of hepatotoxicity in the 
WHO pharmacovigilance database but no reports of 





Fig. 3 Immunohistochemical staining of lymphocytic infiltration. Most lymphoid cells within the portal tracts and sinusoids were CD3 positive T 
cells (A), with some CD20 and CD79a positive B cells present within portal tracts but not extending into the surrounding hepatic parenchyma (B, C). 
























































































































Fig. 4 Evolution of liver biochemistry since starting zanubritinib
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As shown in Table  2, the indication for ibrutinib in 
three out of four case reports was refractory Walden-
ström’s macroglobulinaemia, as in our case. The age of 
patients ranged from 48 to 77, and the pattern of liver 
injury was hepatocellular in all cases, similar to the zan-
ubrutinib case. The time of onset of DILI in our patient, 
30 months, was significantly longer than reported cases 
of ibrutinib-induced DILI cases, ranging from 2 weeks 
to 9 months. The course of DILI, however, was similar 
to other cases, with liver biochemistry normalisation 
within 8 weeks after cessation of the drug. The RUCAM 
score was reported in one case as “probable” [15], and 
we calculated the updated RUCAM scoring using the 
available published data in the other case reports. The 
causality assessment for the first published case report 
of ibrutinib was “unlikely” due to an unexplained recur-
rent increase of liver enzymes and lack of hepatitis A 
Table 1 Liver profile and serological liver screen
Lab values Normal range Virology screen
ALT (IU/L) 2474 0–45 IgM anti-HAV Negative
AST (IU/L) 1257 0–35 HBsAg Negative
ALP (IU/L) 114 40–130 Anti-HCV Negative
Total Bilirubin (umol/L) 141 0–21 IgM anti-HEV Negative
Albumin (g/L) 38 35–52 HEV RNA Not detected
Prothrombin time (s) 14 10–12 IgM anti-CMV Negative
Lipase (U/L) 23 0–67 CMV DNA Not detected
a1-antitrypsin(g/L) 2.0 1.0–2.1 IgM anti-EBV Negative
Paracetamol (mg/L) < 10 < 10 EBV DNA Not detected
Ferritin (ug/L) 4558 25–350 Autoimmune liver screen
Caeruloplasmin (g/L) 0.282 0.2–0.6 ANA Negative
IgG (mg/dL) 740 530–1650 AMA Negative
IgA (mg/dL) 100 70–400 ASMA Negative
IgM (mg/dL) 400 50–190 LKM-1 Negative
Table 2 Summary of case reports of other BTK inhibitors-induced liver injuries
a RUCAM score was not reported; it was calculated based on the published data in the case report
Author title and date Nandikolla, 2017 [14] Kahn 2017 [15] Kleijwegt 2019 [16] Tafesh 2019 [17]
Underlying illness Relapsing, refractory CLL Refractory WM Refractory WM Refractory WM
BTK inhibitor Ibrutinib Ibrutinib Ibrutinib Ibrutinib
Patient’s age and gender 62-year-old male 59-year-old female 48-year-old female 77-year-old Female
Time of liver injury since 
starting BTK inhibitor
2 weeks 9 months 11 weeks 2 months
Pattern of DILI Hepatocellular Hepatocellular Hepatocellular Hepatocellular
Causality assessment/
RUCAM
1 “Unlikely”a 7 “probable” 8 “probable”a 6 “possible”a
Liver histology Centrilobular intrahepatic 
and canalicular chol-
estasis, ceroid-laden 
macrophages and minor 
apoptosis
Acute hepatitis with mixed 
acute and chronic inflam-
mation and hepatocellular 
cholestasis
Not performed Mixed inflammatory cell 




Intervention Ibrutinib stopped Ibrutinib stopped Ibrutinib stopped Ibrutinib stopped + oral 
prednisolone 60 mg daily 
for 12 days, then tapered 
down.
Outcome Liver enzymes improved 
but did not normalise, and 
the patient died from the 
original illness.
Liver enzymes normalised 
after 60 days
Liver enzymes normalised 
after 5 weeks of stopping 
Ibrutinib
Liver enzymes normal-
ised after 7 weeks and 
remained normal after 3 
months
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serology [14]. In contrast, the other two cases were 
graded as “possible” [17] and “probable” [16].
The histopathology, in this case, was strongly corrobo-
rative of drug-induced aetiology, and the clinical context 
and temporal evolution provided a strong correlation. 
Other differentials such as idiopathic autoimmune hepa-
titis (AIH), large duct obstruction and infection were also 
considered but lacked clinical and serological correla-
tions. The clinical context and the combined acute liver 
injury, with histological evidence of cholestasis with a 
mixed inflammatory infiltrate that included eosinophils, 
indicated causal association with drug aetiology. The liver 
biopsy may indeed be of help in cases, such as ours, to 
support the diagnosis of DILI. Previous studies compar-
ing liver biopsies from patients with DILI and idiopathic 
AIH highlighted that the absence of fibrosis and the pres-
ence of cholestasis favour the diagnosis of DILI [19]. 
Although the definition of drug-induced AIH is not well-
established, immune mechanisms may have contributed 
to this as the event resolved without immunosuppres-
sion. The mixed acute hepatitis picture with cholestasis 
was quite similar to that observed for ibrutinib by Kahn 
[15] and Tafesh [17]. A predominantly cholestatic injury 
was observed in the liver biopsy by Nandikolla [14] for 
ibrutinib, a histopathological pattern that may also be 
possible for the BTK group of drugs. Indeed, as the 
broader literature on DILI suggests, drugs/toxins may 
cause any pattern of liver injury, and it is important to 
meticulously record DILI patterns for new drugs with 
registries and biorepositories.
Zanubrutinib is metabolised in the liver via the 
cytochrome P450 system, largely by CYP 3A4, which is 
susceptible to drug-drug interactions with agents that 
inhibit or induce its activity. In this case, the patient was 
not exposed to any agent that could have interfered with 
the CYP enzymes. In contrast, it is important to note 
that significant inhibition of B cell activity from Bruton’s 
kinase inhibitors can cause viral replication and reactiva-
tion of hepatitis B, which may mimic drug-induced liver 
injury [20].
The pathogenesis of BTK inhibitor-induced liver toxic-
ity remains unclear. Several mechanisms have been pro-
posed, including immune mechanisms due to genetic 
variants, oxidative damage, and direct hepatoxicity via 
mitochondrial dysfunction [21]. Metabolic bioactivation 
of small molecule kinase inhibitors by cytochrome P450 
enzymes and generating chemically reactive products 
is presumed to be the initiating event in tyrosine kinase 
inhibitor-induced hepatotoxicity [22]. Recent in  vitro 
mechanistic studies investigated potential cellular path-
ways of tyrosine kinase inhibitors-induced hepatotoxic-
ity by studying their effect on mitochondrial function 
using hepatic cell lines, HepG2 and HepaRG cells [23, 
24]. It is worth noting that HepG2 cells lack cytochrome 
P450 drug activity, which poses a significant limitation 
to investigate the role of pathways of biotransformation 
[22]. Further mechanistic studies investigating cellular 
signalling and pathways of BTK inhibitors are needed to 
gain a better understanding of the pathogenesis of BTK 
inhibitor-induced liver injury.
In conclusion, physicians should be aware of the poten-
tial liver toxicity of zanubrutinib, which requires vigi-
lance. When suspecting liver injury, zanubrutinib should 
be withheld instantly, and reactivation of hepatitis B must 
be excluded as a potential cause.
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